Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8416 to 8430 of 8989 results

  1. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  2. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  3. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  4. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

    Technology appraisal guidance
    Discontinued

  5. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued

  6. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  7. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  8. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  9. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  10. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  11. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  12. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  13. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

    Technology appraisal guidance
    Discontinued

  14. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    Discontinued Reference number: GID-TA10851

    Technology appraisal guidance
    Discontinued

  15. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    Discontinued Reference number: GID-HST10032

    Highly specialised technologies guidance
    Discontinued